Israeli company Gamida Cell will raise $10 million in an internal round from its shareholders, including an owners’ loan of $4 million. Elbit Medical Technologies, which owns 31.6% of Gamida Cell, will invest $3 million in the round. Gamida Cell develops stem cell therapy products for transplantation and regenerative medicine. It is soon to start a Phase II/III clinical trial of its blood cancer treatment and is due to announce the results later this year. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments